Epirubicin glucuronidation and UGT2B7 developmental expression.
The usefulness of epirubicin in the treatment of adult and childhood malignant diseases is related in part to the potential reduction in cardiac toxicity compared with that of other anthracyclines given at equivalent doses. An important pathway for epirubicin detoxification is UGT2B7-dependent glucuronidation. This study was implemented to provide a preclinical evaluation of the metabolism of epirubicin with respect to age-related changes in epirubicin glucuronidation in pediatric liver microsomes. Rates of epirubicin glucuronidation and levels of UGT2B7 were determined for liver microsomes from four pediatric age categories (n = 32) and one adult age category (n = 8). Both sets of data showed an increase in UGT2B7 activity and content with increasing age. Epirubicin glucuronidation activity in the adult group was statistically higher compared with all pediatric age groups (p < or = 0.01). UGT2B7 expression also was statistically higher in adults compared with children below 11 years of age, with evidence of significant differences in protein levels among the pediatric age categories. A positive correlation (r = 0.68) between UGT2B7 levels and postnatal age was observed, suggesting a progressive increase in UGT2B7 protein expression with increasing age. However, allometric scaling using the (3/4) power rule suggested no difference in activity between any of the pediatric age categories and the adult, although only a single neonatal sample was included in the analysis. In summary, these in vitro data show differences in epirubicin glucuronidation and UGT2B7 content within pediatric age groups and support the use of epirubicin in pediatric patients at least 6 months of age.
Zaya
Matthew J
MJ
Pfizer, Inc., Kalamazoo, MI 49001, USA. matthew.j.zaya@pfizer.com
Hines
Ronald N
RN
Stevens
Jeffrey C
JC
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D015251:Epirubicin / Q000031:analogs & derivatives* / Q000378:metabolism*; D005965:Glucuronates / Q000378:metabolism*; D014453:Glucuronosyltransferase / Q000378:metabolism*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008862:Microsomes, Liver / Q000378:metabolism
D000903:Antibiotics, Antineoplastic; D005965:Glucuronates; C074868:epidoxorubicin glucuronide; D015251:Epirubicin; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase